SCHEMBL501816

SCHEMBL501816

COc1ccc(COc2nc(OCc3ccc(OC)cc3)c(C(C)C)c(C(=O)c3cccc(C=CC#N)c3)n2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 1/20 0.38
TNFRSF1A P19438 1/20 0.37
VNN1 O95497 1/20 0.37
TLR4 O00206 1/20 0.36
TLR2 O60603 1/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
PTPN1 P18031 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
MRGPRX4 Q96LA9 2/20 0.34
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
PPARA Q07869 2/20 0.34
MAOB P27338 3/20 0.33
NR1H4 Q96RI1 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL501815 1.00 SMPD1 (0.38) SMPD1TNFRSF1AVNN1TLR4TLR2
SCHEMBL501068 0.88 RAB9A (0.49) SMPD1TNFRSF1ATLR4TLR2RAB9A
SCHEMBL501467 0.83 SMN1; SMN2 (0.44) SMPD1RAB9ANPC1PTPN1SMN1; SMN2
SCHEMBL14266677 0.71 AKR1C3 (0.33)
SCHEMBL501782 0.71 AKR1C3 (0.33)
SCHEMBL501385 0.67 MAOB (0.42) RAB9ANPC1SMN1; SMN2TP53MAOB
SCHEMBL2853918 0.62 P4HB (0.57) RAB9ANPC1TDP1PTPN1P4HB
SCHEMBL2853921 0.62 P4HB (0.57) RAB9ANPC1TDP1PTPN1P4HB
SCHEMBL501636 0.62 ACMSD (0.37) P4HB
SCHEMBL501635 0.62 ACMSD (0.37) P4HB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106064-B2 administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-01-31 US disclosed
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2010-02-11 US disclosed
EP-2044037-A2 HIV REVERSE TRANSCRIPTASE INHIBITORS Gilead Sciences, Inc. (US) 2009-04-08 EP disclosed
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-03-20 US disclosed
WO-2008016522-A2 HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS POLR2E, POLRMT, POLR2H SMPD1 327/4885TNFRSF1A 4151/4885VNN1 1614/4885
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors POLR2E, POLRMT, POLR2H SMPD1 329/4885TNFRSF1A 4154/4885VNN1 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.